Abstract
Hyperglycemia in hematology inpatients is associated with increased adverse events. Glucocorticoids (GC) are utilized frequently in hematologic disorders, increasing the likelihood of hyperglycemia. We performed a retrospective review of all admissions to our hematology ward from September to November 2012 to evaluate identification and management of GC-induced hyperglycemia. Included admissions had at least 1 dose of GC given during hospitalization. We assessed glucose monitoring strategies, glycemic control quality and hyperglycemia therapies during the first 7 days of GC use. Associations between fasting glucose and infection, readmission or emergency department visit within 30 days of GC initiation were assessed using regression analyses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
